Seeking Alpha

bluesfreak

bluesfreak
Send Message
View as an RSS Feed
View bluesfreak's Comments BY TICKER:
Latest  |  Highest rated
  • Properly Treating Costs: Re-Evaluating The MannKind And Sanofi Partnership [View article]
    Wish you would too.
    Aug 14 12:05 PM | Likes Like |Link to Comment
  • MannKind: Looking Beyond The Short-Term Disappointment [View article]
    Thank you Mr. Rho for an informed article on MNKD. I listened to the conference call last night and the comment made by Dr. Mann was Sanofi's right to review the process, and though the CFO's reply: "Alf, we hadn't decided to reveal that now", or something similar elicited chuckles but I don't think is a cause of concern. One thing that was mentioned and wasn't stated in your article is the availability of insulin by the new supplier in France and Sanofi as a back-up, as well as the supply-line control which I think is extra insurance.
    Aug 12 12:28 PM | Likes Like |Link to Comment
  • Sanofi Appears To Be In The Early Stages Of An Earnings Rebound [View article]
    $MNKD Under your diabetes solutions you will now have to add $SNF partnership with Mannkind announced this morning where they will receive 65% of sales.
    Aug 11 10:04 AM | Likes Like |Link to Comment
  • Blackstone: The Market Is Putting The Wrong Company In The Bargain Bin [View article]
    I note the author is a M.D.; they tend to be taciturn. Still, the skeletal facts on $BX's "health" pass his examination.
    Aug 4 10:58 AM | 2 Likes Like |Link to Comment
  • MannKind: Let It Dip A Bit More, Then Cover/Buy [View article]
    I am glad Jim Cramer's remarks were received favorably by the market but surprised at what he said: something like, "For those who don't know MannKind makes a, a, small diabetes device thing and is looking for a partner." Words to that effect. Not necessarily to obfuscate, just caught off guard I think.
    Jul 30 11:41 AM | 1 Like Like |Link to Comment
  • MannKind: Let It Dip A Bit More, Then Cover/Buy [View article]
    I read someone's recent comment that perhaps Novaris might be the partner since they and MannKind have the same date for their earnings report. I don't put too much faith in this, but one can hope! Long MannKind!
    Jul 28 02:57 PM | 4 Likes Like |Link to Comment
  • 5 More Possible Partners For MannKind's Afrezza, Each With A Strong Diabetes Care Franchise [View article]
    Thank you Psychoanalyst for this article and the one preceding it. Not only have you outlined the possible prospects for marketing this wonderful drug, but you've given us their market niche and histories with insulin products. Well-done.
    Jul 21 10:01 AM | 5 Likes Like |Link to Comment
  • MannKind Poised To Enter Worldwide Insulin Market With Ultra-Rapid-Acting Afrezza [View article]
    Encouraging that the FDA wants pediatric trials.
    Jun 30 01:26 PM | 2 Likes Like |Link to Comment
  • MannKind: Approval For Afrezza Looking More And More Positive As Investors Await FDA Decision [View article]
    A good day for diabetics everywhere. Eager to see the start of the pediatric trials.
    Jun 30 01:24 PM | Likes Like |Link to Comment
  • MannKind: 4 Different Insiders Have Sold Shares During The Last 30 Days [View article]
    Ending a sentence with a preposition is not English used "properly".
    Jun 24 09:56 AM | Likes Like |Link to Comment
  • MannKind Poised To Enter Worldwide Insulin Market With Ultra-Rapid-Acting Afrezza [View article]
    The partnership details will be in effect 6 to 8 weeks after the FDA decision. So I'm not sure if that's good news or not.
    Jun 12 03:07 PM | Likes Like |Link to Comment
  • MannKind: Approval For Afrezza Looking More And More Positive As Investors Await FDA Decision [View article]
    MannKind Exec Currently Speaking at Goldman's Healthcare Conference: Says Mgmt in Talks with Partners for Afrezza, according to Benzinga.
    Jun 12 02:55 PM | Likes Like |Link to Comment
  • MannKind Poised To Enter Worldwide Insulin Market With Ultra-Rapid-Acting Afrezza [View article]
    I just received this alert: "MannKind Exec Currently Speaking at Goldman's Healthcare Conference: Says Mgmt in Talks with Partners for Afrezza". It's from Benzinga. Is this new news?
    Jun 12 02:54 PM | 2 Likes Like |Link to Comment
  • MannKind Poised To Enter Worldwide Insulin Market With Ultra-Rapid-Acting Afrezza [View article]
    Inspiring article. Keep in mind also that the Advisory Committee voted 13-1 in favor of Afrezza for treating Type 1 diabetes: what child would rather inject themselves instead of taking a quick breath on an inhaler? Long MannKind.
    Jun 12 01:09 PM | 4 Likes Like |Link to Comment
  • MannKind: 4 Different Insiders Have Sold Shares During The Last 30 Days [View article]
    I subscribe to the SEC filings from MannKind's website directly to my e-mail. Many of those insider sellers bought shares at around $2.30. Who can blame them for taking the gains? They sold right after the stock price trailed off of it's high of around $11.04. I think it was prudent of them to take some profits now, not that it's indicative of their belief that the FDA won't approve, or will put restrictive labeling on the drug, or that a marketing/manufacturing partner won't be found. I think this author is just presenting some facts, some facts mind you, not what price the insiders originally paid for the stock.
    Jun 10 11:54 AM | 1 Like Like |Link to Comment
COMMENTS STATS
39 Comments
62 Likes